公开(公告)号：US20180364248A1

公开(公告)日：2018-12-20

申请号：US16110687

申请日：2018-08-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Martin Hund ,  Edelgard Anna Kaiser ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Johann Karl

IPC: G01N33/68

Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.

公开(公告)号：US11874282B2

公开(公告)日：2024-01-16

申请号：US16110687

申请日：2018-08-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Martin Hund ,  Edelgard Anna Kaiser ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Johann Karl

IPC: G01N31/00 ,  G01N33/53 ,  G01N33/68 ,  G16B99/00 ,  G16B20/00 ,  G16B25/10

CPC classification number: G01N33/689 ,  G01N33/6893 ,  G16B20/00 ,  G16B25/10 ,  G16B99/00 ,  G01N2333/4703 ,  G01N2333/4745 ,  G01N2800/368 ,  G01N2800/52 ,  G01N2800/60

Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.

公开(公告)号：US20180231570A1

公开(公告)日：2018-08-16

申请号：US15943104

申请日：2018-04-02

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Andrea Horsch ,  Birgit Klapperich ,  Dirk Block ,  Alfred Engel ,  Johann Karl ,  Rosemarie Kientsch-Engel ,  Ekaterina Manuilova ,  Christina Rabe ,  Sandra Rutz ,  Monika Soukupova ,  Ursula-Henrike Wienhues-Thelen ,  Peter Kastner ,  Edelgard Anna Kaiser

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/68 ,  G01N33/74 ,  G01N2333/47 ,  G01N2333/8139 ,  G01N2800/347 ,  G01N2800/50

Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.

公开(公告)号：US10231639B2

公开(公告)日：2019-03-19

申请号：US15132318

申请日：2016-04-19

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Mathias Emil Egermark ,  Edelgard Anna Kaiser ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler ,  Marten Rosenquist ,  Viveka Frykmann-Kull ,  Emma Svennberg ,  Leif Friberg

IPC: A61B5/04 ,  A61B5/046 ,  A61B5/0404 ,  A61B5/0408 ,  G01N33/74

Abstract: The present invention relates to a method of diagnosing whether a subject with no known history of atrial fibrillation is suffering from atrial fibrillation, or not, said method comprising the steps of a) determining the amount of a BNP-type peptide in a sample of said subject; b) comparing the amount the BNP-type peptide to a reference, and c) assessing intermittent ECG recordings obtained from said subject over a period of at least one week by using a handheld ECG device.

公开(公告)号：US20170296078A1

公开(公告)日：2017-10-19

申请号：US15132318

申请日：2016-04-19

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Mathias Emil Egermark ,  Edelgard Anna Kaiser ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler ,  Marten Rosenquist ,  Viveka Frykmann-Kull ,  Emma Svennberg ,  Leif Friberg

IPC: A61B5/046 ,  A61B5/0408 ,  A61B5/0404 ,  G01N33/68

CPC classification number: A61B5/046 ,  A61B5/0404 ,  A61B5/04085 ,  A61B2560/0468 ,  G01N33/74 ,  G01N2800/326

Abstract: The present invention relates to a method of diagnosing whether a subject with no known history of atrial fibrillation is suffering from atrial fibrillation, or not, said method comprising the steps of a) determining the amount of a BNP-type peptide in a sample of said subject; b) comparing the amount the BNP-type peptide to a reference, and c) assessing intermittent ECG recordings obtained from said subject over a period of at least one week by using a handheld ECG device.